Announcement • Mar 07
HEM Pharma Inc., Annual General Meeting, Mar 26, 2026 HEM Pharma Inc., Annual General Meeting, Mar 26, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 145, gwanggyo-ro, yeongtong-gu, gyeonggi-do, suwon South Korea New Risk • Jan 23
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Announcement • Oct 31
HEM Pharma Inc. announced that it has received KRW 15.9 billion in funding from Friend Investment Partners Co., Ltd., Pyxis Innovations, Inc., Samsung Securities Co.,Ltd., Mirae Asset Securities Co., Ltd., Hanyang Securities Co. Ltd. On October 30, 2025, HEM Pharma Inc. announced that it has received KRW 15,900,000,000 in funding and closed the transaction.